


[The Long \(Un\)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies](#)



Since the beginning of the COVID-19 pandemic, the United States Food and Drug Administration (“FDA”) has issued more than eighty (80) guidance documents describing flexibilities that would be available to manufacturers of medical devices, drugs and biological products, and foods during the public health emergency. Several of these guidance documents have been modified, updated, or withdrawn as circumstances have changed, and on March 13, 2023, the FDA issued a [notice](#) in the Federal Register that outlines how it intends to unwind a large swath of COVID-19-related guidance documents that are still in effect. FDA sorted seventy-two (72) COVID-19-related guidances into several categories, based on how long and in what form they will continue to be in effect after the expiration of the public health emergency declaration, which is expected on May 11, 2023.

Read the client alert [here](#).